R&D pipeline
MedinCell’s BEPO-based R&D pipeline advances long‑acting injectable therapies across key areas, developed in‑house and with partners.
medincell.comCrawled Nov 13, 2026
MedinCell’s BEPO-based R&D pipeline advances long‑acting injectable therapies across key areas, developed in‑house and with partners.
UZEDY delivers long‑acting risperidone for adults living with schizophrenia and is the first FDA‑approved product using MedinCell’s BEPO technology.
Medincell reaches a major milestone as the U.S. FDA approves Weltruza, a long-acting olanzapine treatment for adults with schizophrenia.
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan.
Medincell has rescheduled publication of its 2026 half-year financial results to December 9, 2026, from the previously planned December 8 date.
UZEDY continues gaining momentum - 2026 Revenue Outlook Raised to $290-310M
MedinCell is a French biopharmaceutical company improving global health through better adherence, accessibility and sustainable care.
Access key information on Medincell’s stock: live share price, Euronext data, analyst coverage, documentation and the latest investor news.
Medincell developed a proprietary technology platform, earned its first FDA approval, and entered a growth phase through innovation and partnerships.
MedinCell's ethics line enables MedinCell employees, collaborators, and external stakeholders to make a report in accordance with law no. 2016-1691 amended by law no. 2022- 401 of March 21, 2022, and implementing decree 2022-401. A whistleblower is a natural person who reports or discloses, without direct financial consideration and in…
MedinCell designs long-acting therapies to improve global health through innovation.
Medincell promotes ethics, transparency and compliance through clear codes and policies that support responsible innovation and governance.